The exocyclic functionalisation of bis(thiosemicarbazonate) complexes of zinc and copper: the synthesis of monomeric and dimeric species
作者:Martin Christlieb、Harriet S. R. Struthers、Paul D. Bonnitcha、Andrew R. Cowley、Jonathan R. Dilworth
DOI:10.1039/b705087a
日期:——
exocylic imine groups bearing a range of substituents. The zinc complexes can be quantitatively and rapidly transmetallated to the corresponding copper complexes and this route or direct reaction with the free ligand can be used to radiolabel the monomericspecies with (64)Cu. In vivo and in vitro studies of one of the (64)Cu imine complexes shows substantial hypoxic selectivity and high tumour uptake in
Water‐Soluble Palladium(II) Sulfonated Thiosemicarbazone Complexes: Facile Synthesis and Preliminary Catalytic Studies in the Suzuki–Miyaura Cross‐Coupling Reaction in Water
作者:Leah C. Matsinha、Jincheng Mao、Selwyn F. Mapolie、Gregory S. Smith
DOI:10.1002/ejic.201500588
日期:2015.8
very stable in water at 70 °C. Consequently, preliminarycatalytic experiments show the water-soluble complexes to be efficient catalyst precursors in the Suzuki–Miyaura cross-coupling reaction in water. No evidence of homo-coupling was observed and the water-soluble complexes demonstrated versatility in coupling substrates containing various functional groups.
[EN] THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY<br/>[FR] THIOSEMICARBAZONES À ACTIVITÉ ANTI-MDR1
申请人:US HEALTH
公开号:WO2012033601A1
公开(公告)日:2012-03-15
Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure;Formula (I). Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X′, Y, L1′, R1′ and R2′ are as defined herein, is useful in medical imaging and therapy.
A method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I)
at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II)
R'-NH-R" (II)
wherein R1, R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, wherein compound (II) is reacted via the NH group bridging R' and R" with compound (I) at its reducing end which is not oxidized.